First up on the podcast, people are buying consumer-grade brain wave detectors ostensibly to help with sleep, concentration, and meditation. But as freelance investigative journalist Jonathan Moens describes, companies are getting more than the price of the devices in the exchange—including training data for artificial intelligence models—in many cases without the consent of the user.
Next on the show, we delve into the many uses for glucagonlike peptide-1 (GLP-1) agonist drugs beyond reducing obesity. Host Sarah Crespi talks with one of the special issue editors, Yevgeniya Nusinovich, senior editor at Science, about their potential for everything from improving cognition to combating cancer. Then we hear from Nora Volkow, director of the National Institute on Drug Abuse at the National Institutes of Health, about hopes for using GLP-1 therapies to address addiction to a range of substances.
See the whole special issue here.
This week’s episode was produced with help from Podigy.
Image: Long Wei/VCG via Getty Images
Learn more about your ad choices. Visit megaphone.fm/adchoices
